AKT1 and type 2 diabetes mellitus: In T2DM, impaired insulin signaling hinders upstream AKT from phosphorylating the Ser9 of GSK‐3β, resulting in increased GSK‐3β activity that promotes AD‐like pathologies [21, 22, 23].